ASC 47 - Gannex Pharma
Alternative Names: ASC-47Latest Information Update: 14 Nov 2024
Price :
$50 *
At a glance
- Originator Gannex Pharma
- Class Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis
Most Recent Events
- 07 Nov 2024 Pharmacodynamics data from a preclinical trial in Non-alcoholic steatohepatitis released by Ascletis
- 07 Nov 2024 Pharmacokinetics and adverse event data from a phase I trial in Non-alcoholic steatohepatitis released by Ascletis
- 13 Jul 2024 Phase-I clinical trials in Non-alcoholic steatohepatitis (In volunteers) in Australia (SC) (NCT06427590)